The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The current role of BTK inhibitors in follicular lymphoma
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses the current role of BTK inhibitors in follicular lymphoma, noting that they are primarily used in the third-line setting, particularly for older or frailer patients who require immediate therapy. Prof. Danilov highlights the potential of exploring next-generation BTK-targeting agents, such as BTK degraders, which have immunomodulatory properties and may be efficacious in this disease. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
